Ovarian carcinoma is disease that eludes early diagnosis and has a high mortality rate. In a diagnosis of ovarian carcinoma, one of the most common problems is to distinguish between a primary ovarian and colorectal adenocarcinoma (1). The SM047 antibody, is the product of hybridoma cells derived by fusion of SP2 myeloma cells with splenic lymphocytes of a mouse that had been immunized with a membrane preparation of an ovarian serous cystadenocarcinoma.
-Immunofluorescence-NBP1-97921-img0002.jpg "Immunofluorescence: SM047 Antibody")
The antibody SM047 binds to an epitope that is displayed by a multivalent antigen associated with the glycocalyx of ovarian adenocarcinoma cells. SM047 staining is specific for an ovarian primary, and is useful in determining the origin of an adenocarcinoma when this is not certain on clinical and pathological grounds. SM047 has been reported to be strongly expressed in most ovarian serous adenocarcinomas and in other female genital tract adenocarcinomas, with the exception of ovarian mucinous tumors (2). SM047 is useful in confirming the ovarian origin of an adenocarcinoma especially so in the distinction between a non-mucinous ovarian adenocarcinoma.
Novus Biologicals offers SM047 reagents for your research needs including:
